Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature

@article{Ciccone2016ClinicalOO,
  title={Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature},
  author={Marcia A Ciccone and Asaf Maoz and Jennifer K Casabar and H. Machida and S. Mabuchi and K. Matsuo},
  journal={Expert Opinion on Investigational Drugs},
  year={2016},
  volume={25},
  pages={781 - 796}
}
ABSTRACT Introduction: While serine-threonine kinases (STK) are attractive therapeutic targets in epithelial ovarian cancer, clinical outcomes of STK inhibitors in the management of recurrent disease have not been completely described. Areas covered: A systematic literature review of published clinical studies on STK inhibitors targeting mTOR, MAPK, and aurora kinase pathways in recurrent epithelial ovarian cancer was conducted, revealing 18 clinical trials (497 patients). Pooled analyses were… Expand
Emerging serine-threonine kinase inhibitors for treating ovarian cancer
Rare ovarian tumours. Other treatments for ovarian cancer
Natural Compounds and Derivatives as Ser/Thr Protein Kinase Modulators and Inhibitors
Radiotherapy for isolated recurrent epithelial ovarian cancer: A single institutional experience

References

SHOWING 1-10 OF 89 REFERENCES
Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.
  • D. Matei, M. Sill, +9 authors M. Birrer
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma.
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
  • F. Janku, J. Wheler, +11 authors R. Kurzrock
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer
Overcoming platinum resistance in ovarian carcinoma
Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer: A Study of the Princess Margaret Hospital Phase II Consortium
...
1
2
3
4
5
...